Prostate Cancer | Clinical

Men With High Genetic Risk of Lethal Prostate Cancer May Lower Their Risk With a Healthier Lifestyle

April 10, 2021

According to new research presented during the virtual AACR Annual Meeting 2021, the likelihood of developing metastatic disease or dying of prostate cancer among men with high genetic risk was lowered in men who maintained a healthy lifestyle.

Similar Outcomes of Multiple Hormonal Agents Give Oncologists Novel Treatment Options for Patients With nmCRPC

April 02, 2021

Alicia K. Morgans, MD, MPH, associate professor of Medicine, Feinberg School of Medicine, Northwestern University, reviewed the clinical trial results for multiple hormonal therapies intended to treat prostate cancer. She explained that many of them show similar outcomes.

LuPSMA Therapy Prolongs Survival in Progressive PSMA-Positive mCRPC

March 23, 2021

177Lu-PSMA-617, a targeted radioligand therapy, demonstrated improvement in both progression-free survival and overall survival as treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer compared with best standard of care alone in the phase 3 VISION trial.

Exploring the Potential of PSCA-Targeted CAR T-Cell Therapy to Treat mCRPC

March 23, 2021

Tanya B. Dorff, MD, a medical oncologist at the City of Hope Cancer Center, discusses the reasoning behind using PSCA-targeted chimeric antigen receptor T-cell therapy and the design of this early study in an interview with Targeted Oncology.

Previous Trials Inform Toxicity Profile of Cabozantinib/Atezolizumab in mCRPC

March 18, 2021

Neeraj Agarwal, MD, discusses the possible adverse events of the randomized phase 3 CONTACT-02 trial of cabozantinib plus atezolizumab versus a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.